Andrea Lobo,  —

Gradient Denervation Technologies has raised €14 million (around $14.9 million) in funding to support the clinical development and testing of an ultrasound-based catheter device for the treatment of pulmonary hypertension (PH). The minimally invasive catheter device is designed for use in the pulmonary arteries. It delivers therapeutic ultrasound…

Treatment with treprostinil improved the risk profile in people with inoperable or persistent severe chronic thromboembolic pulmonary hypertension (CTEPH). The risk profile was assessed using a risk score established to predict a response to treatment and survival in people with pulmonary arterial hypertension (PAH), the most common type…

Echocardiography, a noninvasive imaging method to examine heart structure and function, can be useful in making a preliminary diagnosis of pulmonary hypertension and in determining its likely course, according to a review study. “In future, it is important to use multiple echocardiographic parameters for detection and predicting the prognosis…

About one-quarter of the pulmonary arterial hypertension (PAH) patients in a small study showed cognitive deficits, typically mild impairments in executive function and memory. Problems in abilities like executive function — a set of skills that include thinking, self control, and readily accessible memory that’s part of everyday life…

Babies born preterm, or before 37 weeks of pregnancy, were shown to have a higher risk of developing pulmonary hypertension (PH), primarily between the ages of 1 and 3, according to a study in Sweden. Moreover, that risk was seen to increase as the length of the pregnancy decreased,…

Tailored educational videos on healthy eating coupled with online instruction led to helpful dietary changes in a group of pulmonary arterial hypertension (PAH) patients and the likelihood of a better quality of life, a pilot trial in the Netherlands reports. People assigned to one of two diet plans continued…

Algorithm Sciences, which is developing PulmoProst to treat pulmonary arterial hypertension (PAH), has acquired all assets of Flownix Medical, including the Prometra II pump that would deliver the potential therapy. PulmoProst is an infusion formulation of iloprost, a synthetic version of naturally occurring prostacyclin, a substance that…

Tenax Therapeutics has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO), indicating that a patent for TNX-103 — oral levosimendan — is to be granted. The patent is expected to cover the use of TNX-103 for treating people with pulmonary hypertension and…

Team PHenomenal Hope will host its inaugural symposium — PHenomenal Hope 2023: Knowledge, Research & Advocacy in PH — on Dec. 15 in Boston, allowing renowned experts, young researchers, and healthcare providers to share efforts on pulmonary hypertension (PH) clinical research and care. “Team PHenomenal Hope has grown…

Treatment with levosimendan — a medication seen to improve cardiac function — was associated with rapid clinical benefits in preterm infants with heart problems and pulmonary hypertension (PH), a study in Germany reports. The response to treatment was independent of the babies’ birth weight and how far along…

Among people with pulmonary arterial hypertension (PAH), a measure of artery deformity called pulmonary artery longitudinal strain may be a predictor of risk of death, a study in Singapore reports. A GLS — or artery global longitudinal strain — below 9% was associated with a higher risk of death. Moreover,…

The Pulmonary Hypertension Association (PHA) will join together with more than 80 organizations worldwide on May 5 for World PH Day, seeking to raise awareness of the global impact of pulmonary hypertension (PH). This year’s theme is “United to Cure PH,” aimed at recognizing the global advances to…